Table 4.

Logistic regression analyses of association of IGF2BP2 rs1470579 A>C, rs4402960 G>T and IGFBP3 rs2270628 C>T, rs3110697 G>A, and rs6953668 G>A polymorphisms with risk of NSCLC

Genotype	Overall NSCLC cases (n=521) vs controls (n=1,030)				Adenocarcinoma (n=415) vs controls (n=1,030)				Non-adenocarcinoma (n=106) vs controls (n=1,030)
	Crude OR (95% CI)	P-value	Adjusted ORa (95% CI)	P-value	Crude OR (95% CI)	P-value	Adjusted ORa (95% CI)	P-value	Crude OR (95% CI)	P-value	Adjusted ORa (95% CI)	P-value
IGF2BP2 rs1470579 A>C
Additive model	1.05 (0.84–1.32)	0.666	1.03 (0.82–1.30)	0.800	1.04 (0.82–1.33)	0.739	1.03 (0.80–1.33)	0.805	1.09 (0.71–1.66)	0.705	1.04 (0.65–1.66)	0.859
Homozygote model	0.73 (0.48–1.12)	0.154	0.72 (0.46–1.12)	0.143	0.75 (0.47–1.19)	0.214	0.73 (0.46–1.18)	0.200	0.68 (0.29–1.62)	0.383	0.67 (0.26–1.70)	0.393
Dominant model	0.99 (0.80–1.22)	0.899	0.97 (0.78–1.21)	0.775	0.98 (0.78–1.24)	0.877	0.97 (0.77–1.23)	0.814	1.00 (0.67–1.50)	0.987	0.97 (0.62–1.52)	0.893
Recessive model	0.72 (0.47–1.09)	0.122	0.71 (0.46–1.10)	0.121	0.73 (0.47–1.15)	0.180	0.73 (0.46–1.15)	0.174	0.66 (0.28–1.54)	0.336	0.65 (0.26–1.64)	0.364
IGF2BP2 rs4402960 G>T
Additive model	1.06 (0.85–1.33)	0.604	1.03 (0.82–1.30)	0.801	1.05 (0.82–1.34)	0.692	1.03 (0.80–1.33)	0.802	1.10 (0.72–1.68)	0.644	1.03 (0.65–1.65)	0.889
Homozygote model	0.72 (0.47–1.12)	0.147	0.72 (0.46–1.14)	0.162	0.76 (0.47–1.21)	0.243	0.75 (0.47–1.22)	0.251	0.59 (0.23–1.52)	0.278	0.60 (0.22–1.65)	0.324
Dominant model	1.00 (0.80–1.23)	0.960	0.97 (0.78–1.21)	0.797	0.99 (0.79–1.25)	0.946	0.98 (0.77–1.24)	0.857	1.01 (0.67–1.51)	0.983	0.96 (0.61–1.49)	0.840
Recessive model	0.71 (0.46–1.09)	0.114	0.71 (0.46–1.12)	0.139	0.74 (0.47–1.18)	0.203	0.75 (0.46–1.20)	0.222	0.57 (0.23–1.44)	0.237	0.59 (0.22–1.60)	0.303
IGFBP3 rs2270628 C>T
Additive model	1.03 (0.82–1.30)	0.803	1.01 (0.79–1.28)	0.945	0.94 (0.73–1.21)	0.647	0.92 (0.71–1.19)	0.504	1.42 (0.93–2.15)	0.101	1.43 (0.90–2.27)	0.127
Homozygote model	1.18 (0.70–1.98)	0.542	1.13 (0.66–1.95)	0.648	1.20 (0.69–2.08)	0.520	1.19 (0.68–2.09)	0.550	1.07 (0.37–3.10)	0.896	1.11 (0.35–3.52)	0.857
Dominant model	1.05 (0.84–1.30)	0.695	1.02 (0.81–1.29)	0.852	0.97 (0.76–1.23)	0.809	0.95 (0.74–1.21)	0.658	1.38 (0.92–2.07)	0.123	1.40 (0.89–2.18)	0.145
Recessive model	1.16 (0.70–1.95)	0.564	1.13 (0.66–1.93)	0.654	1.22 (0.71–2.11)	0.476	1.22 (0.70–2.14)	0.485	0.95 (0.33–2.69)	0.916	0.97 (0.31–3.04)	0.963
IGFBP3 rs3110697 G>A
Additive model	1.03 (0.82–1.29)	0.789	1.02 (0.80–1.28)	0.902	0.94 (0.73–1.20)	0.609	0.93 (0.72–1.19)	0.549	1.46 (0.97–2.21)	0.073	1.53 (0.97–2.43)	0.068
Homozygote model	1.17 (0.79–1.73)	0.439	1.18 (0.79–1.79)	0.420	1.20 (0.79–1.82)	0.390	1.21 (0.79–1.85)	0.388	1.02 (0.45–2.32)	0.965	0.89 (0.36–2.19)	0.805
Dominant model	1.05 (0.85–1.30)	0.632	1.04 (0.84–1.30)	0.712	0.98 (0.78–1.24)	0.875	0.97 (0.77–1.23)	0.820	1.38 (0.93–2.06)	0.113	1.41 (0.91–2.19)	0.129
Recessive model	1.15 (0.79–1.69)	0.467	1.18 (0.79–1.75)	0.426	1.23 (0.82–1.84)	0.319	1.24 (0.82–1.89)	0.306	0.86 (0.39–1.92)	0.716	0.74 (0.31–1.77)	0.501
IGFBP3 rs6953668 G>A
Additive model	1.01 (0.71–1.43)	0.963	1.05 (0.73–1.51)	0.808	0.92 (0.63–1.36)	0.681	0.94 (0.63–1.40)	0.772	1.36 (0.75–2.48)	0.309	1.45 (0.74–2.83)	0.277
Homozygote model	0.99 (0.18–5.42)	0.990	0.60 (0.11–3.40)	0.562	0.62 (0.07–5.52)	0.664	0.48 (0.05–4.40)	0.519	2.53 (0.28–22.91)	0.408	1.32 (0.13–13.49)	0.816
Dominant model	1.01 (0.71–1.42)	0.980	1.02 (0.71–1.46)	0.908	0.91 (0.62–1.33)	0.623	0.92 (0.62–1.36)	0.679	1.40 (0.79–2.51)	0.253	1.44 (0.75–2.76)	0.272
Recessive model	0.99 (0.18–5.40)	0.988	0.60 (0.11–3.38)	0.559	0.62 (0.07–5.55)	0.668	0.49 (0.05–4.42)	0.522	2.44 (0.27–22.02)	0.427	1.26 (0.12–12.93)	0.844

Note:

^aAdjusted for age, sex, smoking status, alcohol use, and BMI status.

Abbreviations: NSCLC, non-small-cell lung cancer; BMI, body mass index.